Parkinson's drug discontinuation study: safety first
NCT ID NCT07214285
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows one Parkinson's patient who has been receiving A-dopamine directly into the brain via a pump for years. The goal is to monitor safety during long-term use and manage a gradual, individualized dose reduction until the treatment stops, switching to an alternative like Scyova. It aims to prevent complications from abrupt discontinuation.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
A-dopamine (anaerobic dopamine) delivered via intracerebral pump
What this could lead to
If successful, this study could show that gradual dose reduction and switching to alternative treatments like Scyova is safe for Parkinson's patients.
What could go wrong
This is a very small follow-up study (only 1 participant) focused on safety, not effectiveness. The treatment is being discontinued, so it won't provide new evidence on long-term benefits.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UHLillle
Lille, Haut de France, 59000, France